Physician profile
Samuel Ecker
NPI 1033555230
$2,588.19
in general payments reported to CMS, 2019-2025
27 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $422 · 2021: $503 · 2022: $353 · 2023: $457 · 2024: $481 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.84 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $978.59 | 2020-2024 | Skyrizi, Botox, Rinvoq |
| Lilly USA, LLC | $291.67 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $286.30 | 2019-2025 | |
| Janssen Biotech, INC. | $166.62 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $126.75 | 2021-2024 | Dupixent |
| Pfizer INC. | $80.58 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $77.09 | 2019-2023 | Winlevi |
| Revance Therapeutics, INC. | $49.90 | 2024 | Daxxify |
| Dermira, INC. | $48.30 | 2020 | |
| Almirall LLC | $43.30 | 2019-2021 | |
| Ucb, INC. | $42.87 | 2021-2024 | Bimzelx |
| Genzyme Corporation | $37.67 | 2021-2022 | |
| Dermavant Sciences, INC. | $35.87 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $34.08 | 2023 | |
| Verrica Pharmaceuticals INC. | $33.95 | 2024 | Ycanth |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $33.87 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Organogenesis INC. | $32.56 | 2023 | Puraply |
| Amgen INC. | $30.60 | 2020 | |
| Galderma Laboratories, L.P. | $30.35 | 2023-2024 | |
| Vyne Pharmaceuticals INC. | $20.20 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.69 | 2024 | Sotyktu |
| Journey Medical Corporation | $16.69 | 2022 | |
| Aclaris Therapeutics, INC. | $16.50 | 2019 | |
| Genentech USA, INC. | $15.67 | 2019 | |
| Incyte Corporation | $14.77 | 2023 | Opzelura |
| Epi Health, LLC | $13.69 | 2021 | |
| Allergan, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Ecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.